Skip to content
Gold Mining News – Lifestyle
Author:
Candel Therapeutics
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
September 30, 2026
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
September 30, 2026
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
September 10, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 1, 2026
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 13, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2026
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
August 3, 2026
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
July 29, 2026
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 8, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 1, 2026
1
2
Next Page
→